Back to search

Article

Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline glioma

2020-09-10

Abstract excerpt

<title>Abstract</title> <p>Patients with diffuse midline glioma (DMG) harboring H3 K27M mutation have no proven therapies beyond radiation. ONC201, a DRD2 antagonist and mitochondrial ClpP agonist, has induced early responses in patients with H3 K27M-mutant DMG. We performed an integrated pre-clinical and clinical assessment of ONC201 treatment, in order to define response rates in H3 K27M-mutant DMG patients and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7c2f6d97-970c-5ce7-af00-1f83a4bdf68d
DOI
10.21203/rs.3.rs-69706/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline gliomaDOI 10.21203/rs.3.rs-69706/v1
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.Semantic proximity
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.Semantic proximity
Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.Semantic proximity
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.Semantic proximity
Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.Semantic proximity
Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.Semantic proximity
New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline GliomaSemantic proximity
Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.Semantic proximity
H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.Semantic proximity
Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.Semantic proximity
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.Semantic proximity
Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adultsSemantic proximity
Select a neighboring publication to make it the new centre.